101 results
8-K
EX-1.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability … internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
writing prospectus provided in connection with this offering. Neither we nor the underwriters take any responsibility for, and provide no assurance … , and there can be no assurance that the IRS will agree with such statements and conclusions or will not take a contrary position regarding the tax
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. You should not assume … to the statements made and the conclusions reached in the
S-18
following summary, and there can be no assurance that the IRS will agree
8-K
EX-99.1
ocsjufj4c1pvo
10 Apr 24
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
7:02am
8-K
EX-99.1
bje109fxkk
11 Mar 24
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
7:02am
8-K
EX-99.1
tmht2ysb 9ud3
15 Feb 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
4:01pm
8-K
EX-99.2
bcyfbgr7 6pc1s9y
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
s0yvq ejjk
8 Jan 24
Regulation FD Disclosure
7:03am
8-K
EX-99.1
nmah41vgciv935q8 e9
11 Dec 23
Other Events
12:03pm
8-K
EX-99.1
60u rjh8pk
13 Nov 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
lzgzeg
1 Nov 23
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
4:02pm